NCT03659578View on ClinicalTrials.gov

Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

69

Participants

Timeline

Start Date

August 9, 2018

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Concurrent chemotherapy

Concurrent chemotherapy consists of weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡), each of 1 day's duration.

RADIATION

split-course radiotherapy

Patient was administered with 51 Gy in 17 fractions or 40 Gy in 10 fractions as the first course followed by a break of four weeks. Patients without disease progression had a dose of 15 Gy in 5 fractions or 24 Gy in 6 fractions as a boost

DRUG

thymosin alpha 1

subcutaneous injections of thymosin once a week,1.6mg each time from the start of radiation to 2 months after the end of radiation.

Trial Locations (1)

510000

Sun yat-sen University Cancer Center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER

NCT03659578 - Study of Thymosin α1 to Reduce Acute Pneumonia For Bulky None-small Cell Lung Cancer | Biotech Hunter | Biotech Hunter